KORU Medical Systems (KRMD) reported a Q3 loss of $0.02 per share, exceeding the Zacks Consensus Estimate of a $0.03 loss and improving from a $0.03 loss a year ago. The company also posted revenues of $10.4 million for the quarter ended September 2025, surpassing consensus by 7.07% and up from $8.18 million year-over-year. Despite these beats, KRMD shares have underperformed the S&P 500 year-to-date, losing 3.1% against the index's 16.4% gain, and currently hold a Zacks Rank #3 (Hold) indicating expected in-line market performance.
KORU Medical Systems (KRMD) reported a Q3 loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a $0.03 loss and improving from a $0.03 loss a year ago. The company also posted revenues of $10.4 million, exceeding the consensus estimate by 7.07% and marking a significant increase from $8.18 million in the prior year. This quarter represents an earnings surprise of +33.33%, following a +100% surprise in the previous quarter. Despite these positive quarterly beats, KRMD shares have underperformed the broader market, losing 3.1% year-to-date compared to the S&P 500's 16.4% gain. The company has consistently surpassed consensus revenue estimates three times and EPS estimates two times over the last four quarters. However, the sustainability of immediate price movements hinges on management's commentary during the upcoming earnings call. The stock currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market in the near future. This is influenced by a mixed trend in earnings estimate revisions prior to the release. Positively, KRMD operates within the Medical Info Systems industry, which is ranked in the top 20% of Zacks industries, historically outperforming lower-ranked sectors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
